| Literature DB >> 28415591 |
Tobias Müller1,2, Susanne Fay1, Rodolfo Paula Vieira1, Harry Karmouty-Quintana3, Sanja Cicko1, Korcan Ayata1, Gernot Zissel1, Torsten Goldmann4, Giuseppe Lungarella5, Davide Ferrari6, Francesco Di Virgilio6, Bernard Robaye7, Jean-Marie Boeynaems7, Michael R Blackburn3, Marco Idzko1.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a devastating disease with few available treatment options. Recently, the involvement of purinergic receptor subtypes in the pathogenesis of different lung diseases has been demonstrated. Here we investigated the role of the purinergic receptor subtype P2Y2 in the context of fibrotic lung diseases.The concentration of different nucleotides was measured in the broncho-alveolar lavage (BAL) fluid derived from IPF patients and animals with bleomycin-induced pulmonary fibrosis. In addition expression of P2Y2 receptors by different cell types was determined. To investigate the functional relevance of P2Y2 receptors for the pathogenesis of the disease the bleomycin model of pulmonary fibrosis was used. Finally, experiments were performed in pursuit of the involved mechanisms.Compared to healthy individuals or vehicle treated animals, extracellular nucleotide levels in the BAL fluid were increased in patients with IPF and in mice after bleomycin administration, paralleled by a functional up-regulation of P2Y2R expression. Both bleomycin-induced inflammation and fibrosis were reduced in P2Y2R-deficient compared to wild type animals. Mechanistic studies demonstrated that recruitment of neutrophils into the lungs, proliferation and migration of lung fibroblasts as well as IL6 production are key P2Y2R mediated processes.Our results clearly demonstrate the involvement of P2Y2R subtypes in the pathogenesis of fibrotic lung diseases in humans and mice and hence support the development of selective P2Y2R antagonists for the treatment of IPF.Entities:
Keywords: ATP; chemotaxis; neutrophils; nucleotides; pulmonary fibrosis
Mesh:
Substances:
Year: 2017 PMID: 28415591 PMCID: PMC5482630 DOI: 10.18632/oncotarget.16414
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Elevated ATP levels in patients suffering from pulmonary fibrosis
ATP levels in BAL fluid obtained during bronchoscopy from patients with IPF (n = 22) and healthy volunteers (n = 11) were determined using a luminometric assay. ***p < 0.001.
Patient characteristics
| FEV1 | TLC | DLCOc | Age | sex | treatment for ILD | |
|---|---|---|---|---|---|---|
| 1 | 82 | 65 | 43 | 71 | m | no |
| 2 | 54 | 56 | 31 | 49 | m | no |
| 3 | 77 | 58 | 36 | 89 | m | no |
| 4 | 55 | 69 | N/A | 84 | m | no |
| 5 | 94.2 | 82 | 94.5 | 61 | m | no |
| 6 | 72.9 | 76.4 | 61.8 | 73 | f | no |
| 7 | 55 | 75 | N/A | 55 | m | no |
| 8 | 76.5 | 68.3 | 49.7 | 82 | m | no |
| 9 | 88 | 66 | 50 | 80 | m | prednisone |
| 10 | 54.7 | 62.5 | 17.7 | 51 | m | no |
| 11 | 39.4 | 35.1 | 9 | 59 | m | prednisone |
| 12 | 86.1 | 75.3 | N/A | 86 | m | no |
| 13 | 56.2 | 58.2 | 33.1 | 75 | m | prednisone |
| 14 | 51.9 | 61.5 | 52.5 | 55 | m | prednisone |
| 15 | 65.9 | 55.5 | 35.5 | 73 | f | study drug |
| 16 | 50.4 | 44.1 | 31.6 | 61 | m | Prednisone study drug |
| 17 | 43 | 62.5 | 47.8 | 63 | m | no |
| 18 | 59.9 | 66.5 | 29.8 | 58 | m | prednisone |
| 19 | 41.3 | 48.8 | N/A | 65 | f | prednisone azathioprine |
| 20 | 53.1 | 65.7 | 39.7 | 73 | f | no |
| 21 | 68.7 | 83.3 | 31.7 | 88 | f | no |
| 22 | 33.7 | 37.3 | 17.2 | 59 | m | prednisone cyclophosphamide |
Figure 2Up-regulation of P2Y2R expression in idiopathic pulmonary fibrosis
(A) Expression of P2Y2 receptor subtypes on BAL cells derived from IPF patients (n = 16) and healthy individuals (n = 10) was determined by quantitative RT-PCR. (B) Neutrophils were isolated from whole blood of IPF patients (n = 9) and healthy individuals (n = 9) and P2Y2R expression was measured by quantitative RT-PCR. (C) Neutrophils were isolated from whole blood derived from IPF patients (n = 5) or healthy volunteers (n = 6). Migration in response to ATP or fMLP as a positive control was assessed using the Boyden chamber. *p < 0.05; ***p < 0.001.
Figure 3Elevated intrapulmonary nucleotide levels following bleomycin exposure in mice
(A) Male C57Bl/6 mice received an i. t. injection of BLM or vehicle on day 0. Animals were killed at the indicated time points and ATP levels were measured (n = 4–5 per group). (B–C) Mice received ATP-dependent luciferase-expressing HEK293 cells, followed by an i. t. injection of BLM or vehicle on day 0. Bioluminescence was quantified at the indicated time points (n = 3–6 per group). (D) Male C57Bl/6 mice received an i. t. injection of BLM or vehicle on day 0. Animals were killed at the indicated time points and UTP levels were measured (n = 4–5 per group). *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 4P2Y2R expression in bleomycin induced pulmonary fibrosis
Male C57Bl/6 mice received an i. t. injection of BLM or vehicle on day 0. Animals were killed at the indicated time points and P2R expression in lung tissue was analysed by quantitative RT-PCR (n = 3–5 per group). *p < 0.05.
Figure 5P2Y2R-deficient animals are partially protected from bleomycin induced lung injury and fibrosis
P2Y2R-deficient or wild type mice received an i. t. injection of BLM or vehicle on day 0 and were killed 7, 14 or 21 days later. (A) Total and differential cell counts of the BALF were performed. (B) BALF cytokines were measured by ELISA. (C) Collagen contents were quantified in the BAL fluid by Sircol assay (left) and on histological lung slides (middle). α1 procollagen expression was determined by quantitative real time PCR (right). (D) Histological staining of lung slides (H&E). (n = 4–14 per group). *p < 0.05 compared to BLM-treated wt animals at the same time point.
Figure 6Mechanisms in P2Y2R-induced inflammation and fibrosis
(A) Wild type or P2Y2R-deficient (P2Y2R−/−) animals received an i. t. injection of ATP. BAL was performed after 24 h, and the number of BALF neutrophils and macrophages was determined. *p < 0.05 compared to ATP-treated wild type animals. (B) Primary lung fibroblasts were generated from wild type or P2Y2R-deficient animals. Migration towards ATP (100 μM) was analysed via Boyden chamber (n = 3 per group). (C) Proliferation rate of primary lung murine fibroblasts derived from wild type or P2Y2R-deficient animals (left) or human fibroblasts (right) after stimulation with ATP or UTP. (n = 3–5 per group). *p < 0.05 compared to vehicle stimulated cells. (D) IL6 release of primary murine lung fibroblasts (left and middle) or human lung fibroblasts (right) stimulated with different nucleotides was measured by ELISA (n = 3–7 per group). *p < 0.05 compared to vehicle-stimulated fibroblasts.